The present disclosure provides recombinant bacteria with elevated production of ethanol and/or n-butanol from ethylene. Methods for the production of the recombinant bacteria, as well as for use thereof for production of ethanol and/or n-butanol are also provided.

The present invention relates to a mutant, non-naturally occurring or transgenic tobacco plant cell comprising: (i) a polynucleotide comprising, consisting or consisting essentially of a sequence encoding a functional nicotine N-demethylase and having at least 95% sequence identity to SEQ ID NO:2; (ii) a polypeptide encoded by the polynucleotide set forth in (i); (iii) a polypeptide comprising, consisting or consisting essentially of a sequence encoding a nicotine N-demethylase and having at least 95% sequence identity to SEQ ID NO:3; or (iv) a construct, vector or expression vector comprising the isolated polynucleotide set forth in (i), and wherein the expression or activity of said nicotine demethylase is reduced as compared to a control tobacco plant cell in which the expression or activity of said nicotine demethylase has not been reduced.

The present invention provides compositions and methods for biosynthetically producing podophyllotoxin intermediates and derivatives including enzymes and their equivalents involved in the biosynthetic production of podophyllotoxin intermediates and derivatives.

The present invention relates to a process for the production of a technical enzyme composition with low viscosity, a genetically modified filamentous fungus cell suitable for production of the technical enzyme composition, the use of such a genetically modified filamentous fungus cell for the production of the technical enzyme composition with low viscosity and a technical enzyme composition with low viscosity produced by such a process.

The present invention is directed to provide novel methods of producing hydroxystilbene. According to the present invention, as a method of producing a compound having the general formula (II),

##STR00001##

in which R.sup.1 to R.sup.3 are each H, OH or OR; R is independently selected from a C1-6 alkyl group and a glycosyl group; and one of R.sup.4 and R.sup.5 is H and the other is OH, 4-hydroxyphenylacetate 3-hydroxylase (HPAH) is administered to a compound having the general formula (I),

##STR00002##

in which R.sup.1 to R.sup.3 are each H, OH or OR; and R is independently selected from a C1-6 alkyl group and a glycosyl group.

A genetically engineered microorganism is provided. The genetically engineered microorganism has a higher expression level of acid-tolerant gene than a source microorganism. The acid-tolerant gene includes at least one of dsdA, dcuC and glaA. A method of preparing the genetically engineered microorganism and a method of producing a target chemical using the genetically engineered microorganism are also provided.

The present invention relates to a recombinant microbial cell for producing at least one compound having structural Formula III from at least one simple carbon source:

##STR00001## wherein the simple carbon source is selected from the group consisting of glucose, sucrose, xylose, arabinose, mannose and glycerol; and wherein the cell comprises a further genetic modification to increase production of L-lysine in the cell from at least one of the simple carbon sources.

The present invention relates to a method for producing, from fatty alcohols, various monomers that are used in the production of synthetic resins.

RNAi agents (e.g., CYP7A1 RNAi agents) for inhibiting the expression of the CYP7A1 gene, compositions including the RNAi agents conjugated to a targeting moiety, and methods of use are described. Also disclosed are pharmaceutical compositions including one or more RNAi agents (e.g., CYP7A1 RNAi agents). Delivery of the RNAi agent(s) to liver cells in vivo inhibits CYP7A1 gene expression and treats a CYP7A1 disease or a CYP7A1-associated disease.